Valbiotis S.A. (ALVAL) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for Valbiotis S.A. in 2026.
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
Latest earnings analysis
Consensus estimates were not available, and Valbiotis S.A. recorded revenue of USD 388.74 thousand while EPS was not provided. There is no prior report available to indicate whether EPS or revenue were ahead of or below expectations.
No dividend history available.
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.
Valbiotis S.A. (ALVAL) last reported earnings on October 9, 2025.
Valbiotis S.A. (ALVAL) is listed on Euronext Paris.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.